Expanding the Arsenal of Lipid-Lowering Therapies

More than 4 decades ago, the advent of statins ushered in a transformative era in lipid-lowering therapy. Since then, a robust and extensive body of clinical evidence has consistently validated the efficacy and safety of statins across diverse patient populations, including those with familial hypercholesterolemia. To date, statins remain the cornerstone of lipid-lowering therapy, offering the advantages of broad accessibility, favorable cost, and proven efficacy. However, long-term adherence remains suboptimal. A range of factors, including both objective adverse effects and perceived statin intolerance, contribute to frequent discontinuation of treatment.